Potential clinical treatment for Ebola pandemic 被引量：1

Potential clinical treatment for Ebola pandemic

导出

摘要 West African countries are currently suffering the most severe pandemic of Ebola virus disease ever recorded, with 4269 human cases and 2288 deaths （through 6 September 2014）, and the number of cases in the current outbreak exceeds the number from all previous outbreaks combined. Ebola virus disease was first described in 1976 originating from the Ebola River in the Democratic Republic of the Congo. Five Ebola viruses have been reported to cause Ebola virus pandemics, including Zaire Ebola virus, Sudan Ebola virus, Ivory Coast Ebola virus, Reston Ebola virus and Bundibugyo Ebola virus. The Zaire Ebola virus is the most deadly with a fatality rate up to 90%. Unfortunately, the current outbreak in the West African countries is caused by the Zaire Ebola virus, and no specific treatment for the disease is yet available. West African countries are currently suffering the most severe pandemic of Ebola virus disease ever recorded,with4269 human cases and 2288 deaths(through 6 September2014),and the number of cases in the current outbreak exceeds the number from all previous outbreaks combined.Ebola virus disease was first described in 1976 originating from the Ebola River in the Democratic Republic of the Congo.Five Ebola viruses have been reported to

作者 ZHONG Ying XU Jun LI TaiSheng YU XueZhong SHENG MiaoMiao

机构地区 State Key Laboratory of Medical Molecular Biology Department of Biochemistry and Molecular Biology Department of Emergency Medicine Department of Infectious Diseases Laboratory of Molecular Genetics of Aging & Tumor

出处《Science China(Life Sciences)》 SCIE CAS 2014年第10期982-984,共3页 中国科学（生命科学英文版）

关键词埃博拉病毒临床治疗刚果民主共和国扎伊尔死亡人数感染病例象牙海岸传染病

分类号 R512.8 [医药卫生—内科学]

引文网络
相关文献

参考文献15

1Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VⅡa/tissue factor: a study in rhesus monkeys. Lancet, 2003, 362: 1953-1958.
2Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res, 2014, 105: 17-21.
3Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 2014, 508: 402-405.
4Olinger GG, Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA, 2012, 109: 18030-18035.
5Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med, 2010, 16: 991-994.
6Uebelhoer LS, Albarino CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res, 2014, 106: 86-94.
7Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A,Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehar J, Hensley LE, White JM, Olinger GG. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Translat Med, 2013, 5:190ra179.
8Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pohlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother, 2014, 69: 2123-2131.
9Dokuzoguz B, Celikbas AK, Gok SE, Baykam N, Eroglu MN, Ergonul O. Severity scoring index for crimean-congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis, 2013, 57: 1270-1274.
10Lee W, Ku SK, Bae JS. Barrier protective effects of rutin in LPS-induced inflammation in vitro and in vivo. Food Chem Toxicol, 2012, 50: 3048-3055.